Nouvelle publication pour l’unité PHAR2 :

Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations

(a) Timeline of Klebsiella pneumoniae isolation and antimicrobial therapy. All antibiotics were administered intravenously, except for colistin, which was nebulized. Only antibiotics administered for at least 2 days are presented. Resp.: respiratory. Only Klebsiella pneumoniae isolates in bold were stored and available for retrospective analysis.

Le céfiderocol, une céphalosporine conjuguée à un sidérophore, est un médicament prometteur utilisé pour traiter les infections causées par des bactéries gram-négatives résistantes aux carbapénèmes. Cette étude rapporte un cas de pneumonie provoquée par plusieurs pathogènes gram-négatifs, ayant développé une résistance au céfiderocol en l’espace de 32 jours de traitement.

Pour découvrir les résultats détaillés ⬇️

unité PHAR2 ; Julien Buyck

English version 🇬🇧

New Study by PHAR2:

Emergence of cefiderocol resistance during therapy in NDM-5-producing Klebsiella pneumoniae isolates harboring siderophore receptors mutations

(a) Timeline of Klebsiella pneumoniae isolation and antimicrobial therapy. All antibiotics were administered intravenously, except for colistin, which was nebulized. Only antibiotics administered for at least 2 days are presented. Resp.: respiratory. Only Klebsiella pneumoniae isolates in bold were stored and available for retrospective analysis.

Cefiderocol, a siderophore-conjugated cephalosporin, is a promising drug for treating infections caused by carbapenem-resistant gram-negative bacteria. This study reports a case of pneumonia caused by several gram-negative pathogens, which developed resistance to cefiderocol within 32 days of treatment.

For detailed results ⬇️